BioCentury | Feb 28, 2020
Deals
Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal
...rights to three preclinical zinc finger protein transcription factors (ZFP-TFs) from Sangamo Therapeutics Inc. (NASDAQ:SGMO): ST-501...
...blockage of tau. At its R&D day in December, Sangamo presented preclinical data from the ST-501...
...blockage of tau. At its R&D day in December, Sangamo presented preclinical data from the ST-501...
